The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VACC | -36.8% | N/A | N/A | -95% |
| S&P | +14.77% | +87.2% | +13.35% | +66% |
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.
No news articles found for Barinthus Biotherapeutics Plc.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | -100.0% |
| Gross Profit | -$895.59K | -106.6% |
| Gross Margin | 90.15% | 0.0% |
| Market Cap | $50.44M | 8.2% |
| Market Cap / Employee | $480.34K | 0.0% |
| Employees | 105 | -19.2% |
| Net Income | -$14,483.49K | -76.4% |
| EBITDA | -$6,614.04K | -1477.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $75.67M | -28.7% |
| Accounts Receivable | $0.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.55M | -10.6% |
| Short Term Debt | $2.02M | 1.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -50.98% | -23.2% |
| Return On Invested Capital | -28.04% | 23.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10,599.62K | 42.7% |
| Operating Free Cash Flow | -$10,599.80K | 42.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.30 | 0.30 | 0.33 | 0.49 | 65.46% |
| Price to Sales | 3.10 | 3.19 | 2.59 | 2.48 | -99.10% |
| Price to Tangible Book Value | 0.38 | 0.36 | 0.40 | 0.61 | 59.45% |
| Enterprise Value to EBITDA | 3.72 | 3.39 | 2.83 | 1.99 | -98.20% |
| Return on Equity | -38.5% | -45.4% | -53.8% | -62.3% | 90.25% |
| Total Debt | $12.01M | $11.92M | $11.99M | $11.57M | -8.67% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
